Glaxo (GSK) Up 3.2% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for GSK (GSK). Shares have added about 3.2% in that time frame, underperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Glaxo due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

How Have Estimates Been Moving Since Then?

It turns out, estimates revision have trended upward during the past month.

The consensus estimate has shifted 6.14% due to these changes.

VGM Scores

Currently, Glaxo has an average Growth Score of C, a grade with the same score on the momentum front. However, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Glaxo has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.

Performance of an Industry Player

Glaxo is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Astrazeneca (AZN), a stock from the same industry, has gained 0.5%. The company reported its results for the quarter ended March 2025 more than a month ago.

Astrazeneca reported revenues of $13.59 billion in the last reported quarter, representing a year-over-year change of +7.2%. EPS of $1.24 for the same period compares with $1.03 a year ago.

For the current quarter, Astrazeneca is expected to post earnings of $1.11 per share, indicating a change of +12.1% from the year-ago quarter. The Zacks Consensus Estimate has changed -1.8% over the last 30 days.

Astrazeneca has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research